188 related articles for article (PubMed ID: 35362393)
21. BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Huang WC; Hsieh YL; Hung CM; Chien PH; Chien YF; Chen LC; Tu CY; Chen CH; Hsu SC; Lin YM; Chen YJ
PLoS One; 2013; 8(12):e83627. PubMed ID: 24391798
[TBL] [Abstract][Full Text] [Related]
22. New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
Niu L; Liu L; Yang S; Ren J; Lai PBS; Chen GG
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):564-570. PubMed ID: 29054475
[TBL] [Abstract][Full Text] [Related]
23. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
24. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
[TBL] [Abstract][Full Text] [Related]
25. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
26. ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR.
Shao Z; Li Y; Dai W; Jia H; Zhang Y; Jiang Q; Chai Y; Li X; Sun H; Yang R; Cao Y; Feng F; Guo Y
Pharmacol Res; 2018 Sep; 135():188-200. PubMed ID: 30114438
[TBL] [Abstract][Full Text] [Related]
27. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
28. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
[TBL] [Abstract][Full Text] [Related]
29. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
30. LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells.
Ma Y; Xu R; Liu X; Zhang Y; Song L; Cai S; Zhou S; Xie Y; Li A; Cao W; Tang X
Int J Med Sci; 2021; 18(6):1456-1464. PubMed ID: 33628103
[No Abstract] [Full Text] [Related]
31. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
32. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
33. COX-2/PGE2 Axis Regulates HIF2α Activity to Promote Hepatocellular Carcinoma Hypoxic Response and Reduce the Sensitivity of Sorafenib Treatment.
Dong XF; Liu TQ; Zhi XT; Zou J; Zhong JT; Li T; Mo XL; Zhou W; Guo WW; Liu X; Chen YY; Li MY; Zhong XG; Han YM; Wang ZH; Dong ZR
Clin Cancer Res; 2018 Jul; 24(13):3204-3216. PubMed ID: 29514844
[No Abstract] [Full Text] [Related]
34. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
[TBL] [Abstract][Full Text] [Related]
35. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
36. Tivantinib: critical review with a focus on hepatocellular carcinoma.
Rota Caremoli E; Labianca R
Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
38. Target immune components to circumvent sorafenib resistance in hepatocellular carcinoma.
Wei S; Wei F; Li M; Yang Y; Zhang J; Li C; Wang J
Biomed Pharmacother; 2023 Jul; 163():114798. PubMed ID: 37121146
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
40. The role of tyrosine kinase inhibitors in hepatocellular carcinoma.
Kim S; Abou-Alfa GK
Clin Adv Hematol Oncol; 2014 Jan; 12(1):36-41. PubMed ID: 25000314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
